WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SYRE

Based on 7 analysts offering 12 month price targets for Spyre Therapeutics Inc

Min Forecast
$43.00-5.87%
Avg Forecast
$62.29+36.35%
Max Forecast
$92.00+101.4%

Should I buy or sell SYRE stock?

Based on 7 analysts offering ratings for Spyre Therapeutics Inc.

Strong Buy
Strong Buy
6 analysts 85.71%
Buy
1 analysts 14.29%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SYRE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SYRE as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their SYRE stock forecasts and price targets.

SYRE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-18Find Out Why
lockedlocked$00.00+00.00%2026-03-16
lockedlocked$00.00+00.00%2026-02-20
lockedlocked$00.00+00.00%2025-12-18
lockedlocked$00.00+00.00%2025-12-17
Jones Trading
Top 28%
73
Strong BuyUpgrades$64.00+40.11%2025-12-01
Deutsche Bank
Top 10%
91
Strong BuyInitiates Coverage On$43.00-5.87%2025-09-26

1 of 1

Forecast return on equity

Is SYRE forecast to generate an efficient return?

Company
-40.05%
Industry
68.89%
Market
178.41%
SYRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SYRE forecast to generate an efficient return on assets?

Company
-36.83%
Industry
31.74%
SYRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SYRE earnings per share forecast

What is SYRE's earnings per share in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
-$2.99
Avg 2 year Forecast
-$3.22
Avg 3 year Forecast
-$3.45

SYRE revenue forecast

What is SYRE's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SYRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SYRE$45.68$62.29+36.35%Strong Buy
NAMS$31.01$47.00+51.56%Strong Buy
DNLI$22.47$29.25+30.17%Strong Buy
DNTH$79.61$128.90+61.91%Strong Buy
KNSA$45.84$55.50+21.07%Strong Buy
View Top Biotech Stocks

Spyre Therapeutics Stock Forecast FAQ

Is Spyre Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: SYRE) stock is to Strong Buy SYRE stock.

Out of 7 analysts, 6 (85.71%) are recommending SYRE as a Strong Buy, 1 (14.29%) are recommending SYRE as a Buy, 0 (0%) are recommending SYRE as a Hold, 0 (0%) are recommending SYRE as a Sell, and 0 (0%) are recommending SYRE as a Strong Sell.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.

What is SYRE's earnings growth forecast for 2026-2028?

(NASDAQ: SYRE) Spyre Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.8%.

Spyre Therapeutics's earnings in 2026 is -$155,203,000.On average, 16 Wall Street analysts forecast SYRE's earnings for 2026 to be -$235,212,083, with the lowest SYRE earnings forecast at -$307,107,749, and the highest SYRE earnings forecast at -$165,759,016. On average, 15 Wall Street analysts forecast SYRE's earnings for 2027 to be -$253,087,824, with the lowest SYRE earnings forecast at -$374,071,093, and the highest SYRE earnings forecast at -$116,278,713.

In 2028, SYRE is forecast to generate -$271,238,456 in earnings, with the lowest earnings forecast at -$386,386,191 and the highest earnings forecast at -$97,311,263.

What is SYRE's revenue growth forecast for 2026-2028?

(NASDAQ: SYRE) Spyre Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.36%.

Spyre Therapeutics's revenue in 2026 is $0.On average, 15 Wall Street analysts forecast SYRE's revenue for 2026 to be $0, with the lowest SYRE revenue forecast at $0, and the highest SYRE revenue forecast at $0. On average, 13 Wall Street analysts forecast SYRE's revenue for 2027 to be $0, with the lowest SYRE revenue forecast at $0, and the highest SYRE revenue forecast at $0.

In 2028, SYRE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SYRE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SYRE) forecast ROA is -36.83%, which is lower than the forecast US Biotechnology industry average of 31.74%.

What is SYRE's Price Target?

According to 7 Wall Street analysts that have issued a 1 year SYRE price target, the average SYRE price target is $62.29, with the highest SYRE stock price forecast at $92.00 and the lowest SYRE stock price forecast at $43.00.

On average, Wall Street analysts predict that Spyre Therapeutics's share price could reach $62.29 by Mar 18, 2027. The average Spyre Therapeutics stock price prediction forecasts a potential upside of 36.35% from the current SYRE share price of $45.68.

What is SYRE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SYRE) Spyre Therapeutics's current Earnings Per Share (EPS) is -$1.98. On average, analysts forecast that SYRE's EPS will be -$2.99 for 2026, with the lowest EPS forecast at -$3.91, and the highest EPS forecast at -$2.11. On average, analysts forecast that SYRE's EPS will be -$3.22 for 2027, with the lowest EPS forecast at -$4.76, and the highest EPS forecast at -$1.48. In 2028, SYRE's EPS is forecast to hit -$3.45 (min: -$4.92, max: -$1.24).

What is SYRE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SYRE) forecast ROE is -40.05%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.